Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
According to Novo Nordisk's latest financial reports the company's current earnings are S$39.69 Billion. In 2023 the company made an earning of S$20.96 Billion, an increase over its 2022 earnings that were of S$13.30 Billion. The earnings displayed on this page is the company's Pretax Income.